Evaluating whether Aldeyra Therapeutics Inc. (NASDAQ: ALDX) represents a strong buy or sell requires a careful assessment of its clinical pipeline risks and regulatory milestones. Following regulatory setbacks and Complete Response Letters from the FDA regarding its dry eye disease candidate, the stock behaves with high volatility characteristic of clinical-stage biotechnology equities. Proponents view the depressed valuation as a potential turnaround opportunity if regulatory pathways clear, whereas conservative analysts advise caution due to commercialization delays and binary clinical dependencies.